3,4-Dibrom-hexan-2,5-dion | 56101-85-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3,4-Dibrom-hexan-2,5-dion
• 英文别名: 3,4-dibromo-hexane-2,5-dione；3,4-Dibromohexane-2,5-dione；3,4-dibromohexane-2,5-dione
• CAS: 56101-85-0
• 化学式: C₆H₈Br₂O₂
• 分子量: 271.936
• InChiKey: CWSCJKDJTVWUMD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3,4-Dibrom-hexan-2,5-dion 、 1-Thiocarbamoyl-pyrazolid-3-on 生成
  参考文献：
  名称：

  Richter, A. M.; Mojjoukhine, V., Journal fur praktische Chemie (Leipzig 1954), 1982, vol. 324, # 6, p. 873 - 881

  摘要：

  DOI：
• 作为产物：
  描述：

  3-己烯-2,5-二酮 在 氯仿 、 溴 作用下， 生成 3,4-Dibrom-hexan-2,5-dion
  参考文献：
  名称：

  Dithiazolylen的立体立体主义

  摘要：

  Umüberdie Winkelung der NCCN-Gruppe in Dithiazolylen etwas zu erfahren，wurden 4,4'- and 5,5'-Dithiazolylderivate hergestellt und auf das Vorhandensein von Atropisomeriegeprüft。在不合时宜的Verbindungen beobachtet werden的最佳Isomere konnte bei keiner der Biher中进行的Spaltbarkeit。

  DOI：

  10.1002/hlca.19480310722

文献信息

• A convenient one-pot synthesis of thiazol-2-imines: application in the construction of pifithrin analogues
  作者：Siva Murru、C.B. Singh、Veerababurao Kavala、Bhisma K. Patel

  DOI：10.1016/j.tet.2007.11.076

  日期：2008.2

  3-disubstituted thioureas using 1,1′-(ethane-1,2-diyl)dipyridinium bistribromide (EDPBT). Unsymmetrical 1,3-disubstituted thioureas give regioselective products with symmetrical ketones, which are mainly governed by the pKas of NH protons of thiourea, whereas symmetrical 1,3-disubstituted thioureas give regioselective products with symmetrical carbonyl compounds owing to the regioselective bromination of

  首次分离出反应中间体，从而进一步了解了噻唑-2-亚胺的形成机理。反应的第一步需要碱性介质，而第二步是酸介导的E1消除反应。通过使用1,1'-（乙烷-1,2-二基）双吡啶鎓溴化吡啶鎓（EDPBT）将羰基化合物与硫脲和1,3-二取代的硫脲缩合，已实现了有效的一锅合成取代的噻唑-2-亚胺。 ）。不对称的1,3-二取代的硫脲会产生带有对称酮的区域选择性产物，该酮主要由p K a决定。s的是硫脲的NH质子，而对称的1,3-二取代的硫脲由于酮的区域选择性溴化作用而产生具有对称羰基化合物的区域选择性产物。该方法已扩展为在较短的反应时间内以高收率获得新型神经退行性药物候选品菲丝菌素-α类似物。该方法简单，通用，可用于不同的1,3-二取代的硫脲以及一系列羰基化合物。
• Compositions for inhibition of anglogenesis
  申请人：The Children's Medical Center Corporation

  公开号：EP2143444A1

  公开（公告）日：2010-01-13

  The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, anti-inflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.

  本发明包括一组能有效抑制血管生成的化合物。更具体地说，沙利度胺和各种相关化合物，如沙利度胺前体、类似物、代谢物和水解产物，已被证明可抑制血管生成和治疗血管生成导致的疾病状态。此外，抗炎药物，如类固醇和非甾体抗炎药物，可单独或与沙利度胺及相关化合物联合使用，抑制血管生成相关疾病。重要的是，这些化合物可以口服给药。
• Eberson, Lennart; Kubacek, Pavel, Acta Chemica Scandinavica, 1990, vol. 44, # 4, p. 384 - 393
  作者：Eberson, Lennart、Kubacek, Pavel

  DOI：——

  日期：——
• METHOD FOR PREVENTING OR ALLEVIATING THE NOXIOUS EFFECTS RESULTING FROM TOXICANT EXPOSURE
  申请人：Jordt Sven-Eric

  公开号：US20110144137A1

  公开（公告）日：2011-06-16

  The present invention provides a method of using agents which can modulate TRPA1 function as counteragents to inhibit the physical effects of chemical irritants/toxicants when given prior to exposure or to lessen the physical effects when administered post exposure, and more specifically, to a method for counteracting the acute physical noxious effects of toxicants, including but not limited to, tear gases, chlorine, hydrogen peroxide, ammonia, phosgene, chloropicrin, isocyanates and mustard gas. Administering the counteragents counteracts pain, inflammation, lachrymation, blepharospasm, respiratory irritation and depression, airway mucus secretion, airway obstruction and injury, cough and incapacitation and cutaneous chemical injuries. Another embodiment provides a method of preventing or treating a disease or condition in a mammal, which disease or condition includes hypersensitivity to chemical stimuli, particularly in regards to inflammatory airway conditions, such as asthma, rhinitis, etc., by administering to the mammal a therapeutically effective amount of a compound that inhibits TRPA1 function, wherein the compound reduces the hypersensitivity and mediates the response to such chemical stimuli in the mammal. The invention also includes a kit containing the compound that inhibits the TRPA1 function as a counteracting agent for administration prior to or post exposure to prevent or limit the effects of the exposure.